2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

9:00AM-11:00AM: Abstract Number: 216

Inflectra and Remicade Use and Cost in Canada Under Provincial Drug Plans in 2016

Epidemiology and Public Health Poster I: Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 611

Influence of Dose Titration of Concomitant Steroid and Methotrexate during Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice Based on the IORRA Cohort

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 644

Influence of Inflammation and Structural Damage on Global Functioning in Patients with Axial Spondyloarthritis – Using the ASAS Health Index in Routine Care

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 140

Inhibition of Cathepsin S Leads to Suppression of SS-a/SS-B Specific T Cells from Patients with Primary Sjøgren Syndrome

T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 58

Inhibition of Lipid Phosphatase SHIP1 Expands Myeloid-Derived Suppressor Cells and Attenuates Rheumatoid Arthritis in Mice

Rheumatoid Arthritis – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 121

Inhibition of Nuclear Receptor Coactivator 3 Attenuates Fibrosis in Murine Models of Systemic Sclerosis

Systemic Sclerosis and Related Disorders – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 128

Inhibition of Prolyl-tRNA Synthetase As a Novel Therapeutic Target for Systemic Sclerosis

Systemic Sclerosis and Related Disorders – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 450

Injection Site Reaction Associated with Subcutaneous Biologic Agents and Methotrexate. Analysis from the Rhumadata® Clinical Database and Registry

Pain Mechanisms – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 232

Inpatient Mortality in Transition-Aged Youth with Rheumatic Disease: An Analysis of the National Inpatient Sample

Epidemiology and Public Health Poster I: Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 9

Integration of Cytokine Profiles with Distinct B-Cell Functions Reveals a Specific Micro-Environmental Framework in Autoimmune Diseases

B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 3

Interferon-Alpha Disrupts DNA-Specific B Cell Tolerance in 3H9 Mice

B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 52

Interferon-Alpha Protects Against Pain and Joint Damages in Experimental Arthritis and Is Associated with Expansion of Highly Suppressive Regulatory T Lymphocytes in Protected Mice and in Tocilizumab-Treated Rheumatoid Arthritis Patients

Rheumatoid Arthritis – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 613

Interim Analysis of Baseline Characteristics and Preferences of Administration Route of Rheumatoid Arthritis Patients Who Are Bio-Naïve or Switched between Advanced RA Treatments; A Multicenter, Prospective, Observational Study

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 720

Interkeukin-6 Level in Cerebrospinal Fluid As a Biomarker for Systemic Lupus Erythematosus Patients with Longitudinally Extensive Transverse Myelitis like Neuromyelitis Optica Spectrum Disease

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 404

Interleukin 17A– a Translational Target to Treat Supraspinatus Tendinopathy

Orthopedics, Low Back Pain and Rehabilitation Poster – ACR/ARHP

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].